A Phase III Randomized, Double-blind, Placebo Controlled, Multicenter, Bridging Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Sixteen Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy Follow-up to One Year in Chinese Subjects With Active Psoriatic Arthritis
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 15 Jun 2024 Results assessing Efficacy and Safety of Secukinumab in Chinese Patients with Active Psoriatic Arthritis presented at the 25th Annual Congress of the European League Against Rheumatism
- 26 Apr 2023 Status changed from active, no longer recruiting to completed.
- 05 Jan 2023 Planned End Date changed from 28 Aug 2023 to 27 Mar 2023.